An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services
Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to ma...
Saved in:
Published in | Harm reduction journal Vol. 14; no. 1; pp. 52 - 13 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
31.07.2017
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use. |
---|---|
AbstractList | Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care. Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care. Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use. Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care. Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use. Keywords: Harm reduction, Substance abuse, Street drugs, Drug overdose, Drug users, Drug effects, Drug-related side effects and adverse reactions, Drug evaluation Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use. Abstract Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care. Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use. Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use. |
ArticleNumber | 52 |
Audience | Academic |
Author | Harper, Lane Pijl, Em M. Powell, Jeff |
Author_xml | – sequence: 1 givenname: Lane surname: Harper fullname: Harper, Lane – sequence: 2 givenname: Jeff surname: Powell fullname: Powell, Jeff – sequence: 3 givenname: Em M. surname: Pijl fullname: Pijl, Em M. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28760153$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kl1rHCEUhoeS0ny0P6A3RehNbybVUcfxprCEfgQCvWmvxdHjrsuMbnVmQ_59nWyaZkMpIsrxeV898p5XJyEGqKq3BF8S0rUfM2kkZzUmYpmy5i-qM8KEqAUn4uTJ_rQ6z3mLccFp96o6bTrRYsLpWTWsAop7SHsPtyg65GKCkL1BNs1rNEGefFijEaZNtBnpYNG0AZ9Qnv2kez_46W7RoI1OI0pgZzP5GNAu-jDV0dVGJ0B58TeQX1cvnR4yvHlYL6qfXz7_uPpW33z_en21uqkNb_FUOyO0ZaynBEOjOyKhY9I1DlrdgWxEjwHbTjfUOm1bjkUvKZSqYU4bITW9qK4PvjbqrdolP-p0p6L26r4Q01rpNHkzgNK4xR0Ax8Zy1nLWtdpQzjjvHW84W7w-Hbx2cz-CNRCmpIcj0-OT4DdqHfeKcyqkbIvBhweDFH_N5UPV6LOBYdAB4pwVkQ1vBGWCFvT9M3Qb5xTKV91TkmJO2r_UWpcGfHCx3GsWU7XihDSLlSzU5T-oMiyM3pQcOV_qR4J3Txt97PBPVgpADoBJMecE7hEhWC15VIc8qpLFZUrFi0Y805iSmyUi5TV--I_yN-uC5Gg |
CitedBy_id | crossref_primary_10_1002_dta_2750 crossref_primary_10_1108_DHS_12_2022_066 crossref_primary_10_3390_chemosensors12040058 crossref_primary_10_1111_dar_13237 crossref_primary_10_1111_imj_14742 crossref_primary_10_1016_j_socscimed_2022_115229 crossref_primary_10_1186_s12954_023_00882_y crossref_primary_10_1186_s13011_023_00590_7 crossref_primary_10_1016_j_aca_2019_12_051 crossref_primary_10_3390_bs10080121 crossref_primary_10_1371_journal_pone_0288656 crossref_primary_10_1016_j_bios_2021_113002 crossref_primary_10_1016_j_drugalcdep_2023_111028 crossref_primary_10_1002_wfs2_1455 crossref_primary_10_1039_C8AN02464B crossref_primary_10_1016_j_fsigen_2021_102559 crossref_primary_10_1021_acsami_3c03722 crossref_primary_10_1108_DHS_10_2022_0035 crossref_primary_10_1111_dar_13004 crossref_primary_10_1371_journal_pone_0292812 crossref_primary_10_1016_j_rinp_2019_102680 crossref_primary_10_1016_j_drugalcdep_2020_108006 crossref_primary_10_1111_dar_13370 crossref_primary_10_1186_s13011_018_0156_3 crossref_primary_10_1016_j_forc_2023_100475 crossref_primary_10_1039_D4LC00223G crossref_primary_10_1016_j_procbio_2021_12_021 crossref_primary_10_1021_acsomega_4c08614 crossref_primary_10_1002_wfs2_1461 crossref_primary_10_1016_j_snb_2024_137215 crossref_primary_10_1111_dar_13816 crossref_primary_10_1002_dta_3022 crossref_primary_10_1080_10408347_2020_1802219 crossref_primary_10_3390_s22103877 crossref_primary_10_1002_dta_2973 crossref_primary_10_1109_TBCAS_2024_3405815 crossref_primary_10_33084_bjop_v4i2_1978 crossref_primary_10_1097_PHH_0000000000001581 crossref_primary_10_1016_j_ejpb_2022_08_017 crossref_primary_10_1016_j_talanta_2020_120987 crossref_primary_10_1016_j_drugalcdep_2017_12_026 crossref_primary_10_1177_0033354920915439 crossref_primary_10_1007_s00216_022_03924_9 crossref_primary_10_1007_s11030_021_10289_1 crossref_primary_10_3390_bios10030022 crossref_primary_10_1016_j_forc_2023_100489 crossref_primary_10_1111_dar_13829 crossref_primary_10_1007_s10404_023_02674_z crossref_primary_10_1007_s00216_021_03670_4 crossref_primary_10_1016_j_jmr_2021_107138 crossref_primary_10_3389_fpubh_2022_983663 crossref_primary_10_1016_j_drugpo_2021_103409 crossref_primary_10_1111_dar_13825 crossref_primary_10_1016_j_forsciint_2019_110135 crossref_primary_10_1016_j_forc_2021_100331 crossref_primary_10_1002_jrs_6133 crossref_primary_10_1007_s12088_024_01303_9 crossref_primary_10_1016_j_drugpo_2024_104560 crossref_primary_10_1016_j_chroma_2023_463980 crossref_primary_10_1021_jasms_0c00295 crossref_primary_10_1002_ange_201910177 crossref_primary_10_1016_j_jelechem_2021_114994 crossref_primary_10_12998_wjcc_v11_i21_4996 crossref_primary_10_1016_j_drugpo_2018_08_007 crossref_primary_10_1016_j_drugalcdep_2019_01_045 crossref_primary_10_1002_wfs2_1371 crossref_primary_10_1016_j_drugalcdep_2021_108976 crossref_primary_10_1039_D0AN01246G crossref_primary_10_1186_s40814_023_01321_2 crossref_primary_10_1016_j_dadr_2024_100247 crossref_primary_10_3390_s23135856 crossref_primary_10_1007_s00216_020_02571_2 crossref_primary_10_1016_j_chemolab_2021_104265 crossref_primary_10_1016_j_talanta_2022_123264 crossref_primary_10_1080_09687637_2024_2330938 crossref_primary_10_1186_s12954_024_01004_y crossref_primary_10_1186_s12954_021_00478_4 crossref_primary_10_1186_s12954_023_00856_0 crossref_primary_10_1016_j_drugalcdep_2019_01_035 crossref_primary_10_1016_j_talanta_2022_123945 crossref_primary_10_1021_acs_analchem_9b00507 crossref_primary_10_1021_jasms_0c00112 crossref_primary_10_1016_j_drugpo_2019_06_018 crossref_primary_10_1016_j_electacta_2023_142009 crossref_primary_10_1016_j_snb_2022_132923 crossref_primary_10_1016_j_drugpo_2023_104086 crossref_primary_10_1016_j_jpba_2022_114728 crossref_primary_10_1016_j_scijus_2018_11_006 crossref_primary_10_1186_s12954_018_0276_0 crossref_primary_10_1007_s00216_022_04274_2 crossref_primary_10_1055_a_2167_2177 crossref_primary_10_1080_03067319_2023_2261008 crossref_primary_10_1080_08897077_2019_1616245 crossref_primary_10_1016_j_drugpo_2018_10_001 crossref_primary_10_1039_D2SD00043A crossref_primary_10_1111_add_15734 crossref_primary_10_1021_jasms_1c00232 crossref_primary_10_3389_ijph_2023_1605955 crossref_primary_10_15406_frcij_2024_13_00433 crossref_primary_10_1016_j_jsat_2021_108418 crossref_primary_10_1016_j_forc_2021_100363 crossref_primary_10_1016_j_forc_2022_100443 crossref_primary_10_1016_j_talanta_2018_12_095 crossref_primary_10_1016_j_drugalcdep_2018_10_017 crossref_primary_10_1016_j_jpba_2022_114950 crossref_primary_10_1080_02791072_2022_2028203 crossref_primary_10_1002_rcm_9179 crossref_primary_10_1080_00952990_2023_2226312 crossref_primary_10_1016_j_drugalcdep_2018_11_033 crossref_primary_10_1021_acs_analchem_9b00176 crossref_primary_10_1016_j_vibspec_2023_103567 crossref_primary_10_1186_s12954_023_00921_8 crossref_primary_10_3389_fpsyt_2021_596895 crossref_primary_10_1515_revac_2022_0046 crossref_primary_10_1111_dar_13909 crossref_primary_10_1016_j_toxac_2025_01_094 crossref_primary_10_1186_s12954_024_00937_8 crossref_primary_10_1016_j_trac_2022_116828 crossref_primary_10_1016_j_forc_2021_100370 crossref_primary_10_1021_acs_analchem_2c01630 crossref_primary_10_1016_j_chemolab_2022_104574 crossref_primary_10_1016_j_drugalcdep_2025_112631 crossref_primary_10_1007_s00216_019_01644_1 crossref_primary_10_1038_s41598_020_60824_7 crossref_primary_10_1186_s12954_024_01014_w crossref_primary_10_3390_chemosensors10030108 crossref_primary_10_1149_1945_7111_ac6c4f crossref_primary_10_1016_j_scijus_2022_12_006 crossref_primary_10_1016_j_drugalcdep_2020_108416 crossref_primary_10_1002_pam_22048 crossref_primary_10_1186_s12954_018_0252_8 crossref_primary_10_3390_ijerph20115999 crossref_primary_10_1016_j_trac_2021_116447 crossref_primary_10_1039_D2AN01856J crossref_primary_10_1016_j_ab_2020_113619 crossref_primary_10_1016_j_drugpo_2019_09_017 crossref_primary_10_1063_5_0046281 crossref_primary_10_1016_j_talanta_2024_126217 crossref_primary_10_1371_journal_pone_0274401 crossref_primary_10_1038_s43856_024_00642_4 crossref_primary_10_1097_PHH_0000000000002061 crossref_primary_10_1016_j_drugpo_2023_104206 crossref_primary_10_1080_10408347_2020_1785837 crossref_primary_10_3390_mps3020043 crossref_primary_10_1016_j_forc_2024_100572 crossref_primary_10_1111_1468_0009_12470 crossref_primary_10_15446_rev_colomb_quim_v52n1_108752 crossref_primary_10_1016_j_disamonth_2024_101851 crossref_primary_10_2139_ssrn_3997566 crossref_primary_10_1016_j_saa_2022_121684 crossref_primary_10_1186_s12954_021_00585_2 crossref_primary_10_3390_molecules26216713 crossref_primary_10_1016_j_japh_2023_12_015 crossref_primary_10_1186_s12954_024_01098_4 crossref_primary_10_1016_j_snb_2023_133766 crossref_primary_10_2105_AJPH_2017_304270 crossref_primary_10_1002_jrs_6520 crossref_primary_10_1002_mrc_5156 crossref_primary_10_1002_anie_201910177 crossref_primary_10_1016_j_talo_2022_100114 crossref_primary_10_1186_s13063_020_04898_8 crossref_primary_10_1177_29767342231212787 crossref_primary_10_1186_s12954_023_00836_4 crossref_primary_10_1016_j_drugpo_2020_102661 crossref_primary_10_31412_rbcp_v14i11_972 crossref_primary_10_1111_1556_4029_14437 crossref_primary_10_1177_10406387211070539 crossref_primary_10_1186_s12954_023_00764_3 crossref_primary_10_1016_j_snb_2021_131274 crossref_primary_10_1002_smll_202104847 crossref_primary_10_1080_08839514_2021_1966882 crossref_primary_10_1111_1556_4029_14318 crossref_primary_10_1039_D3RA06931A crossref_primary_10_1080_00387010_2018_1501703 crossref_primary_10_1007_s11292_024_09643_8 crossref_primary_10_1016_j_drugpo_2020_102845 crossref_primary_10_3390_ijerph20064793 crossref_primary_10_3390_psychoactives2010001 crossref_primary_10_1021_acsomega_9b00302 crossref_primary_10_1080_10408347_2021_1958196 crossref_primary_10_1155_2020_8869713 crossref_primary_10_1016_j_drugpo_2020_102973 crossref_primary_10_1007_s00764_024_00319_7 crossref_primary_10_1016_j_chroma_2023_464097 crossref_primary_10_1016_j_snb_2019_04_053 crossref_primary_10_1111_imj_14258 crossref_primary_10_1002_dta_2605 crossref_primary_10_2139_ssrn_3397354 crossref_primary_10_1364_AO_423466 crossref_primary_10_1021_acschemneuro_1c00498 crossref_primary_10_1111_dar_12882 crossref_primary_10_1021_jasms_2c00090 crossref_primary_10_1016_j_jpba_2019_03_063 crossref_primary_10_1016_j_cll_2025_01_005 crossref_primary_10_1021_acssuschemeng_3c03517 crossref_primary_10_3390_s23063140 crossref_primary_10_1016_j_forsciint_2022_111277 crossref_primary_10_1177_00037028231160565 crossref_primary_10_1111_dar_12887 crossref_primary_10_3390_s23136201 crossref_primary_10_1002_elan_12034 crossref_primary_10_1016_j_addbeh_2020_106529 crossref_primary_10_1186_s12954_019_0336_0 crossref_primary_10_3389_fceng_2022_1112876 crossref_primary_10_1108_DHS_07_2022_0026 crossref_primary_10_1146_annurev_anchem_061020_124221 crossref_primary_10_1080_10826076_2024_2448692 crossref_primary_10_1016_j_forsciint_2020_110498 crossref_primary_10_1080_10826084_2020_1753773 crossref_primary_10_3390_ijerph191911960 crossref_primary_10_1080_10826084_2023_2231067 crossref_primary_10_1149_1945_7111_abba8f crossref_primary_10_1016_j_snb_2020_129303 crossref_primary_10_1007_s00604_021_04851_9 crossref_primary_10_1016_j_drugpo_2021_103334 crossref_primary_10_1016_j_forsciint_2018_05_001 crossref_primary_10_1016_j_drugpo_2020_103037 crossref_primary_10_1021_acs_analchem_1c04512 crossref_primary_10_1016_j_saa_2021_120819 crossref_primary_10_1108_DHS_01_2022_0007 crossref_primary_10_1136_bmjopen_2023_076111 |
Cites_doi | 10.1016/S0731-7085(96)01939-5 10.1002/dta.1969 10.1016/S0379-0738(99)00235-2 10.5694/mja15.01058 10.1111/add.13056 10.1007/3-540-29623-9_5050 10.1002/dta.1954 10.1039/B906433H 10.1002/jrs.4864 10.3109/15563658608992606 10.1002/jrs.1250201108 10.1080/00387011003601044 10.1016/j.forsciint.2013.07.012 10.1016/j.forc.2017.04.001 10.1081/SL-120038765 10.1039/c2an15953h 10.1016/j.forsciint.2010.08.005 10.1007/s11419-008-0041-2 10.1080/05704928.2011.625748 10.1002/dta.1949 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 The Author(s). 2017 |
Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 – notice: The Author(s). 2017 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA ATCPS AZQEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S M1P PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PYCSY 7X8 5PM DOA |
DOI | 10.1186/s12954-017-0179-5 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Medical Database Environmental Science Database ProQuest Central Premium ProQuest One Academic ProQuest Open Access Content Collection ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work |
EISSN | 1477-7517 |
EndPage | 13 |
ExternalDocumentID | oai_doaj_org_article_a0608ee50cd5465486ac35455bf5254a PMC5537996 A511234739 28760153 10_1186_s12954_017_0179_5 |
Genre | Journal Article Review |
GeographicLocations | Canada |
GeographicLocations_xml | – name: Canada |
GroupedDBID | --- 0R~ 29I 2WC 2XV 53G 5GY 5VS 7X7 7XC 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACHQT ACIHN ACUHS ADBBV ADRAZ ADUKV AEAQA AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IHR INH INR IPY ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PATMY PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PYCSY RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7XB 8FK AHSBF AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c560t-fc7ad44b310e2a819e849f2fe6a8e927b0e0d8a23dfad6507b93e7b0c4fac79a3 |
IEDL.DBID | M48 |
ISSN | 1477-7517 |
IngestDate | Wed Aug 27 01:09:10 EDT 2025 Thu Aug 21 18:30:57 EDT 2025 Thu Jul 10 18:00:41 EDT 2025 Fri Jul 25 21:27:10 EDT 2025 Tue Jun 17 21:47:41 EDT 2025 Tue Jun 10 20:08:22 EDT 2025 Mon Jul 21 05:49:03 EDT 2025 Tue Jul 01 00:46:55 EDT 2025 Thu Apr 24 23:01:36 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Drug users Drug-related side effects and adverse reactions Drug effects Drug evaluation Harm reduction Substance abuse Drug overdose Street drugs |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c560t-fc7ad44b310e2a819e849f2fe6a8e927b0e0d8a23dfad6507b93e7b0c4fac79a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/1925930516?pq-origsite=%requestingapplication% |
PMID | 28760153 |
PQID | 1925930516 |
PQPubID | 105462 |
PageCount | 13 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a0608ee50cd5465486ac35455bf5254a pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537996 proquest_miscellaneous_1925273473 proquest_journals_1925930516 gale_infotracmisc_A511234739 gale_infotracacademiconefile_A511234739 pubmed_primary_28760153 crossref_primary_10_1186_s12954_017_0179_5 crossref_citationtrail_10_1186_s12954_017_0179_5 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-07-31 |
PublicationDateYYYYMMDD | 2017-07-31 |
PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-31 day: 31 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Harm reduction journal |
PublicationTitleAlternate | Harm Reduct J |
PublicationYear | 2017 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | YS Manimala (179_CR20) 2016; 5 CAF Oliveira Penido de (179_CR26) 2016; 47 179_CR3 Q Li (179_CR41) 2012; 137 N Forsgard (179_CR19) 2010; 25 DF Rendle (179_CR31) 2003; 19 JK Brown (179_CR9) 1973; 13 JR Verkouteren (179_CR21) 2011; 206 D Sorak (179_CR25) 2012; 47 TM Brunt (179_CR16) 2017; 9 AA Bunaciu (179_CR23) 2010; 45 179_CR14 179_CR15 E Sisco (179_CR22) 2017; 4 Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) (179_CR24) 2006 CM Hodges (179_CR28) 1989; 20 RA Engh (179_CR30) 2006 179_CR35 D Trzybiński (179_CR32) 2013; 232 EC Klatt (179_CR10) 1986; 24 RJ Butterfield (179_CR7) 2016; 204 Canadian Community Epidemiology Network on Drug Use (179_CR1) 2015 Standing Committee on Health (179_CR13) 2016 NV Phadnis (179_CR33) 1997; 15 CL O’Neal (179_CR37) 2000; 109 KM Elkins (179_CR38) 2017; 9 J Mounteney (179_CR4) 2016; 111 JA Marshman (179_CR11) 1974 C Sage (179_CR12) 2016 MP Elie (179_CR34) 2009 Canadian Institute for Health Information (179_CR2) 2016 RB Cody (179_CR18) 2005; 40 EMA Ali (179_CR27) 2017; 9 Trans European Drugs Information (TEDI) Workgroup (179_CR5) 2011 European Monitoring Centre for Drugs and Drug Addiction (179_CR6) 2001 K Kanai (179_CR36) 2008; 26 KA Frederick (179_CR29) 2004; 37 179_CR40 W Tregoning (179_CR8) 2016 JSC Tsai (179_CR17) 2005 A Dasgupta (179_CR39) 2009 |
References_xml | – start-page: 471 volume-title: Encyclopedia of analytical chemistry year: 2009 ident: 179_CR34 – volume: 15 start-page: 929 issue: 7 year: 1997 ident: 179_CR33 publication-title: J Pharm Biomed Anal doi: 10.1016/S0731-7085(96)01939-5 – volume: 13 start-page: 670 issue: 12 year: 1973 ident: 179_CR9 publication-title: J Am Pharm Assoc – volume: 9 start-page: 256 issue: 2 year: 2017 ident: 179_CR27 publication-title: Drug Test Anal doi: 10.1002/dta.1969 – volume: 109 start-page: 189 issue: 3 year: 2000 ident: 179_CR37 publication-title: Forensic Sci Int doi: 10.1016/S0379-0738(99)00235-2 – volume: 204 start-page: 144 issue: 4 year: 2016 ident: 179_CR7 publication-title: Med J Aust doi: 10.5694/mja15.01058 – volume-title: Executive Agency for Health and Consumers year: 2011 ident: 179_CR5 – volume-title: An inventory of on-site pill-testing interventions in the EU: fact files year: 2001 ident: 179_CR6 – volume: 111 start-page: 34 issue: 1 year: 2016 ident: 179_CR4 publication-title: Addiction doi: 10.1111/add.13056 – ident: 179_CR15 – start-page: 2026 volume-title: Encyclopedic reference of genomics and proteomics in molecular medicine year: 2006 ident: 179_CR30 doi: 10.1007/3-540-29623-9_5050 – volume-title: Drug checking at music festivals: a how-to guide year: 2016 ident: 179_CR12 – start-page: 1242 volume-title: Encyclopedia of analytical chemistry year: 2009 ident: 179_CR39 – volume: 9 start-page: 188 issue: 2 year: 2017 ident: 179_CR16 publication-title: Drug Test Anal doi: 10.1002/dta.1954 – volume: 25 start-page: 74 issue: 1 year: 2010 ident: 179_CR19 publication-title: J Anal At Spectrom doi: 10.1039/B906433H – volume: 47 start-page: 28 issue: 1 year: 2016 ident: 179_CR26 publication-title: J Raman Spectrosc doi: 10.1002/jrs.4864 – ident: 179_CR3 – volume: 40 start-page: 8 issue: 1 year: 2005 ident: 179_CR18 publication-title: JEOL News – volume: 24 start-page: 441 issue: 5 year: 1986 ident: 179_CR10 publication-title: J Toxicol Clin Toxicol doi: 10.3109/15563658608992606 – start-page: 29 volume-title: Drug-testing technologies and applications year: 2005 ident: 179_CR17 – volume: 20 start-page: 745 issue: 11 year: 1989 ident: 179_CR28 publication-title: J Raman Spectrosc doi: 10.1002/jrs.1250201108 – volume-title: Street drug analysis and its social and clinical implications year: 1974 ident: 179_CR11 – volume-title: Deaths involving fentanyl in Canada, 2009–2014 year: 2015 ident: 179_CR1 – volume: 45 start-page: 206 issue: 3 year: 2010 ident: 179_CR23 publication-title: Appl Spectrosc Rev doi: 10.1080/00387011003601044 – volume-title: Hospitalizations and emergency department visits due to opioid poisoning in Canada year: 2016 ident: 179_CR2 – volume-title: Drug checking services year: 2016 ident: 179_CR8 – volume: 232 start-page: e28 issue: 1 year: 2013 ident: 179_CR32 publication-title: Forensic Sci Int doi: 10.1016/j.forsciint.2013.07.012 – ident: 179_CR35 – volume: 4 start-page: 108 year: 2017 ident: 179_CR22 publication-title: Forensic Chemistry doi: 10.1016/j.forc.2017.04.001 – volume: 37 start-page: 301 issue: 3 year: 2004 ident: 179_CR29 publication-title: Spectrosc Lett doi: 10.1081/SL-120038765 – volume: 137 start-page: 1596 issue: 7 year: 2012 ident: 179_CR41 publication-title: Analyst doi: 10.1039/c2an15953h – volume: 5 start-page: 118 issue: 2 year: 2016 ident: 179_CR20 publication-title: J Pharm Anal – ident: 179_CR40 – volume-title: Supplemental document SD-2 for part IVB, quality assurance/validation of analytical methods year: 2006 ident: 179_CR24 – ident: 179_CR14 – volume: 206 start-page: 190 issue: 1–3 year: 2011 ident: 179_CR21 publication-title: Forensic Sci Int doi: 10.1016/j.forsciint.2010.08.005 – volume: 26 start-page: 6 issue: 1 year: 2008 ident: 179_CR36 publication-title: Forensic Toxicol doi: 10.1007/s11419-008-0041-2 – volume: 47 start-page: 83 issue: 2 year: 2012 ident: 179_CR25 publication-title: Appl Spectrosc Rev doi: 10.1080/05704928.2011.625748 – volume: 9 start-page: 306 issue: 2 year: 2017 ident: 179_CR38 publication-title: Drug Test Anal doi: 10.1002/dta.1949 – volume-title: Vol. 42nd parliament, 1st session year: 2016 ident: 179_CR13 – volume: 19 start-page: 11 issue: 2 year: 2003 ident: 179_CR31 publication-title: Rigaku J |
SSID | ssj0029538 |
Score | 2.5483632 |
SecondaryResourceType | review_article |
Snippet | Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction... Abstract Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 52 |
SubjectTerms | Analysis Analytical chemistry Canada Care and treatment Color Costs Drug abuse Drug addiction Drug effects Drug overdose Drug testing Drug users Drugs Empowerment Encyclopedias Forensic engineering Forensic science Forensic sciences Fourier transforms Harm Reduction Humans Identification Immunoassays Infrared spectroscopy Ionic mobility Laboratories Legal medicine Mass spectrometry Mass spectroscopy Methods Music festivals Opioids Pharmaceutical Preparations - blood Pharmaceutical Preparations - urine Pharmaceuticals Point of care testing Point-of-Care Systems - legislation & jurisprudence Raman spectroscopy Reduction Reproducibility of Results Review Scientific imaging Street drugs Substance abuse Substance Abuse Detection - legislation & jurisprudence Urine Well being Working groups |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ji9RAFC5kTl7E3XZaKUEUhGKy1HpsxWHw4MnBuRWVWsbGJhmS9MF_73updNNB0IuHXGqBVNVbvpd6-R4hb4uqMaLhNYuxiozH5JiptGOAjFOpAi-jn9g-v8qra_7lRtyclPrCnLBMD5w37sIVstAxisIHrNvNtXS-BrcvmiQguJmgEfi8QzA1h1oG9Hi-wyy1vBhKvM5iaJFRAplYeKGJrP9Pk3zik5b5kicO6PIheTAjR7rJb_yI3IvtY7LOv9fS73GXXB_pO3po6PqfT8hu01LM0cTv_7RLFBAqJqx7Gvr9LR2RYaO9pbmK9EBdG-h0cUCH_XbMBN6_cA5FfmvaI8srniO967btyLrEMG-MDrO5eUquLz9_-3TF5voKzAPOGVnyygXOG0B4sXIADaLmJlUpSqejqVRTxCJoV9UhuQBITjWmjtDqeXJeGVc_I2dt18YXhHolpQ4KsIaXXHIDMCCVInFduCpUsl6R4rDf1s_k41gDY2enIERLm4_IwvHgY6xYkQ_HKXeZeeNvgz_iIR4HImn21ACiZGdRsv8SpRV5jyJgUbXh5byb_1CAJSJJlt0gOK25qs2KrBcjQSX9svsgRHY2CYMFKC0MWNdSrsibYzfOxDS3Nnb7PAb5hhRs2PMsc8clQWgLwbOAHrWQxsWalz3t9sdEGC5ErSCuffk_Numc3K8mPcLP22tyNvb7-Apw2di8nlTwN6FLNC4 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jj9MwFLZguHBB7BQKMhICCcmaLF7iEyqI0YgDJ0b0ZjleSkWVlCQ98O95L3E7EyHNIRcvUpy3-Hv2y_cIeZcVtRY1L1kIRWA8RMt0UVkGyDjmyvM8uJHt87u8vOLf1mKdDtz6lFZ59Imjo_atwzPyc0AiQoNy5vLT_g_DqlF4u5pKaNwl95C6DFO61Po64NJgzekmM6_keZ_jpRZDv4x6yMRsLxop-_93zDd2pnnW5I1t6OIheZDwI11NAn9E7oTmMVlOP9nSn2EXbRfoe3psaLvfT8hu1VDM1MQV0jZSwKmYtu6o7w4bOiDPRrOhUy3pntrG0_H6gPaH7TDReP_FORRZrmmHXK8oTbpvt83A2sgwe4z2yek8JVcXX398uWSpygJzgHYGFp2ynvMacF4oLACEUHEdixikrYIuVJ2FzFe2KH20HvCcqnUZoNXxaJ3StnxGzpq2CS8IdUrKyitAHE5yyTWAgZiLyKvMFr6Q5YJkx-9tXKIgx0oYOzOGIpU0k4gMiAcfbcSCfDxN2U_8G7cN_oxCPA1E6uyxoe02JlmisZnMqhBE5jwWgueVtK4EHCnqKCBatgvyAVXAoIHDyzmb_lOAJSJVllkhRC25KvWCLGcjwTDdvPuoRCY5ht5cq_GCvD1140xMdmtCe5jGIOuQgg_2fNK505IgwIUQWkCPmmnjbM3znmb7a6QNF6JUEN2-vP21XpH7xWgheHy9JGdDdwivAXcN9ZvRuP4BszIsXw priority: 102 providerName: ProQuest |
Title | An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28760153 https://www.proquest.com/docview/1925930516 https://www.proquest.com/docview/1925273473 https://pubmed.ncbi.nlm.nih.gov/PMC5537996 https://doaj.org/article/a0608ee50cd5465486ac35455bf5254a |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_38eKL-G11XSKIghDtRz7aB5E9ueMQPERc3LeQpsne4tKe3S54_70zaXe54iE-7EsyWZpkJvlNZ_obQl7FaVmIkmfMudQx7rxhRZobBsjYJ6riibOB7fNCns_554VYHJBdeathATe3unZYT2rert_9_nX9EQz-QzD4XL7fJBisYnjeon4xcUiO4WJSaKdf-D6oAEKhsHXClYJnSdQQ5Lz1L0bXVGDz__vMvnFpjRMqb9xQZ_fI3QFa0lmvC_fJgasfkEn__S394dbetI6-pruGpv35kKxnNcUkTgwQ0MZTgLCY0W5p1W6XtEMKjnpJ-zLTG2rqiobIAt1sV13P8H2NYygSYNMWaWBxo-lVs6o71niGiWV0M5xHj8j87PT7p3M2FGBgFoBQx7xVpuK8BAjoUgPYweW88Kl30uSuSFUZu7jKTZpV3lQA9VRZZA5aLffGqsJkj8lR3dTuKaFWSZlXCsCIlVzyAnCCT4TneWzSKpVZROLdems7sJNjkYy1Dl5KLnW_RRq2B3-FFhF5ux9y1VNz_Ev4BDdxL4is2qGhaZd6MFJtYhnnzonYVlgjnufS2Awgpii9AEfaROQNqoBGbYSHs2b4hAGmiCxaeoboNeMqKyIyGUmCzdpx906J9E7lNWBtUcDxm8iIvNx340jMg6tds-1lkJBIwYI96XVuPyXwfcG7FtCjRto4mvO4p15dBkZxITIFju-z_57fc3InDcaCL7kn5Khrt-4FoLOunJJDtVBTcnxyevH12zS845gGO_wDjJQ40g |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbK9gAXxJuFBYzEQ0KymjiOkxwQ2kKrLS0VQq3ozXUce1mxSpYkK9Q_xW9kJo-lEVJvPeTiRxTb45lv4vE3hLzyeJqEqQiYtdwyYZ1mCY81A2Ts_CgTvjUN2-exnJ2Kz2fh2Rb509-FwbDKXic2ijorDP4j3wEkEiYgnL78sPrFMGsUnq72KTRasTi0F7_BZaveH3yC9X3N-f7eyccZ67IKMAPWvWbORDoTIgVcY7kGg2hjkTjurNSxTXiUetbLYs2DzOkM8EuUJoGFUiOcNlGiA3jvDbItAnBlRmR7d-_467eNi5eA_ujOTv1Y7lQ-HqMxtAQo-SwcWL8mScD_puCSLRzGaV4yfPt3yO0OsdJpK2J3yZbN75FJe62XfrdLp0tL39C-oCh_3ifLaU4xNhTnlBaOAjLGQHlDs3I9pzUye-Rz2mavrqjOM9ocWNBqvahb4vAL7EORV5uWyC6L8kNXxSKvWeEYxqvRqlNzD8jptazAQzLKi9w-JtREUsZZBBjHSCFFAvDD-aETsad5xmUwJl4_38p0pOeYe2OpGucnlqpdIgXLg0-iwjF5t-myahk_rmq8i4u4aYhk3U1BUc5Vt_eV9qQXWxt6JsPU8yKW2gSAXMPUheCf6zF5iyKgUKXAxxnd3YyAISI5l5oiKA5EFCRjMhm0BFVghtW9EKlOFVXq38YZk5ebauyJ4XW5LdZtG-Q5imDCHrUytxkSuNQg6SHURANpHIx5WJMvfjRE5WEYROBPP7n6s16Qm7OTL0fq6OD48Cm5xZvdgj_PJ2RUl2v7DFBfnT7vthol59e9u_8C_J1sSA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+overview+of+forensic+drug+testing+methods+and+their+suitability+for+harm+reduction+point-of-care+services&rft.jtitle=Harm+reduction+journal&rft.au=Harper%2C+Lane&rft.au=Powell%2C+Jeff&rft.au=Pijl%2C+Em+M&rft.date=2017-07-31&rft.pub=BioMed+Central+Ltd&rft.issn=1477-7517&rft.eissn=1477-7517&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs12954-017-0179-5&rft.externalDocID=A511234739 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon |